Treatment of Carbapenem-Resistant Klebsiella pneumoniae with Concurrent Enterococcus faecalis
For dual infection with carbapenem-resistant Klebsiella pneumoniae (CRKP) and Enterococcus faecalis, use combination therapy targeting both organisms: ceftazidime-avibactam (if KPC-producing) or polymyxin-based combination for CRKP, plus ampicillin for E. faecalis coverage. 1, 2
Algorithmic Approach to Treatment Selection
Step 1: Determine CRKP Carbapenemase Type
The carbapenemase profile fundamentally determines optimal therapy:
For KPC-producing CRKP (most common in many regions):
- First-line: Ceftazidime-avibactam is the preferred agent for serine carbapenemase producers 1
- If ceftazidime-avibactam resistant: Add a β-lactam to ceftazidime-avibactam (synergy rates 79.7-86.5%) 3
- Alternative: Polymyxin + ceftazidime-avibactam combination (53.2% synergy rate even in polymyxin-resistant isolates) 3
For NDM-producing CRKP (metallo-β-lactamase):
- Ceftazidime-avibactam + aztreonam (83.3% synergistic activity) 3
- This combination works because aztreonam is stable against MBLs while avibactam protects aztreonam from other β-lactamases
For KPC+NDM co-producers:
- Ceftazidime-avibactam + aztreonam showed synergistic or additive effects in 100% of isolates despite individual agent resistance 3
Step 2: Add Enterococcal Coverage
Since E. faecalis is present concurrently, you must add specific enterococcal coverage:
- Ampicillin is the agent of choice for E. faecalis (assuming susceptibility) 2
- This is critical because E. faecalis is intrinsically resistant to cephalosporins and has variable susceptibility to other agents
- If using a regimen that doesn't cover enterococcus (e.g., ceftriaxone-metronidazole for intra-abdominal infections), ampicillin must be added 2
Step 3: Consider Polymyxin-Based Combinations if Newer Agents Unavailable
If ceftazidime-avibactam is not available or the isolate is resistant:
Polymyxin combination therapy is strongly recommended over monotherapy for CRKP infections 1:
- Reduces mortality by 14 fewer deaths per 1000 patients (RR 0.97)
- Reduces treatment failure by 119 fewer failures per 1000 patients (RR 0.82)
- Reduces pathogen eradication failure by 74 fewer failures per 1000 patients (RR 0.81)
Specific polymyxin combinations:
- Polymyxin + carbapenem (meropenem): Use only if meropenem MIC ≤8 mg/L for CRE, with high-dose extended-infusion meropenem (3-hour infusion) 1
- Polymyxin + fosfomycin: If isolate susceptible to fosfomycin (39-99% susceptibility rates in CRKP) 1
- Polymyxin + tigecycline: Demonstrated synergistic activity 1
Critical caveat: Monotherapy with colistin-polymyxin B or tigecycline had 66.7% mortality despite in vitro susceptibility, compared to 13.3% with combination therapy 4. This underscores that combination therapy is essential for bacteremia and serious CRKP infections.
Step 4: Optimize Dosing and Monitoring
Therapeutic drug monitoring (TDM) should be performed for 1:
- Polymyxins (narrow therapeutic index)
- Aminoglycosides (if used)
- Carbapenems (especially high-dose extended-infusion regimens)
Monitor renal function closely during polymyxin treatment and avoid combining with other nephrotoxic or ototoxic agents 1.
Practical Regimen Examples
Scenario 1: KPC-producing CRKP + E. faecalis (ceftazidime-avibactam available)
- Ceftazidime-avibactam 2.5g IV q8h
- PLUS Ampicillin 2g IV q4-6h (for E. faecalis)
Scenario 2: NDM-producing CRKP + E. faecalis
- Ceftazidime-avibactam 2.5g IV q8h + Aztreonam 2g IV q8h
- PLUS Ampicillin 2g IV q4-6h
Scenario 3: CRKP + E. faecalis (newer agents unavailable)
- Colistin (loading dose 9 million units, then 4.5 million units q12h) + Meropenem 2g IV over 3 hours q8h (if MIC ≤8 mg/L)
- PLUS Ampicillin 2g IV q4-6h
- Consider adding fosfomycin if susceptible
Scenario 4: Respiratory tract infection with CRKP + E. faecalis
- Add aerosolized polymyxin to intravenous polymyxin (may reduce mortality by 50 deaths per 1000 patients, RR 0.86) 1
- Continue systemic therapy as above
Critical Pitfalls to Avoid
Do not use monotherapy for CRKP bacteremia or serious infections - mortality approaches 58-67% with monotherapy versus 12-13% with combination therapy 4
Do not forget enterococcal coverage - E. faecalis is intrinsically resistant to cephalosporins and ceftazidime-avibactam; ampicillin must be added 2, 5
Do not combine polymyxin with other nephrotoxic agents without careful monitoring 1
Do not use polymyxin-carbapenem combinations if meropenem MIC >8 mg/L - unlikely to be effective 1
Avoid fosfomycin in patients with hypernatremia or cardiac/renal insufficiency 1
Do not assume in vitro synergy translates to clinical benefit - one study showed colistin-meropenem in vitro synergism did not improve outcomes in severe CRGNB infections 1
Special Considerations
For polymicrobial infections where carbapenem cannot be used (e.g., E. faecium which is intrinsically carbapenem-resistant), consider sulbactam-durlobactam + tigecycline as demonstrated in a recent case report 5. However, this applies to E. faecium, not E. faecalis.
Obtain antimicrobial susceptibility testing and consider synergy testing (checkerboard method, time-killing curves) to guide combination selection, particularly in treatment failures 1.